p-hydroxybenzaldehyde ameliorates Parkinson’s disease by regulating the PI3K/Akt/Nrf2 pathway
p-hydroxybenzaldehyde ameliorates Parkinson’s disease by regulating the PI3K/Akt/Nrf2 pathway
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Publication status: preprint
A plain-language reading has not been prepared for this paper yet.
Original abstract
Abstract p-hydroxybenzaldehyde (p-HBA) is a natural phenolic component, which is an active ingredient in traditional Chinese medicines such as Gastrodia elata Bl. This study aimed to examine the pharmacodynamic effects of p-HBA and its mechanism in PD. A two-point method was used to establish a rat model of PD via stereotactic injection of 6-hydroxydopamine (6-OHDA) into the brain and BV2 cells were treated with MPP + to induce oxidative stress to clarify the target and pathway of p-HBA. The results indicated that p-HBA improved the behavior of PD rats treated with p-HBA. And p-HBA significantly increased the number of TH- and NeuN-positive neurons while reducing the number of α-synuclein-positive neurons in the substantia nigra and improved neuronal cell morphology. ELISA showed that p-HBA decreased the secretion of NO, an oxidative stress-related factor, and increased the expression of GSH-Px, a peroxidase, in the serum of rats with PD. p-HBA reduced LDH and ROS secretion in MPP + -induced oxidative stress damage in BV2 cells and increased SOD and GSH-Px levels. Immunofluorescence and western blotting analysis showed that p-HBA increased the expression of p-PI3K/PI3K, p-AKT/AKT, Nrf2 and HO-1. The above experimental results suggest that, p-HBA may regulate the PI3K/AKT/Nrf2 pathway, alleviating oxidative stress in nerve cells, and preventing the development of PD.